Does the encapsulation of the drug change its biodistribution and change its safety profile?
Vesselon CEO and Co-founder Clay Larsen discusses how his company’s platform can increase how much drug actually gets into a selected tissue by as much as 200-600%.
Does Vesselon have a case study combining the technology with antibody drug conjugates?
Vesselon CEO and Co-founder Clay Larsen and Epistat CEO Dr. Llew Keltner discuss key Vesselon data indicating the company’s platform can get approx. 4x, or 400% more antibody into a tumor.
How can Vesselon’s technology extend drug patent life?
Epistat CEO Dr. Llew Keltner on why Vesselon is confident that its platform can extend the patent life on the Modes of Action.
Is there any evidence of systemic or abscopal effect of Vesselon’s technology?
Epistat CEO Dr. Llew Keltner and Vesselon CEO and Co-founder Clay Larsen discuss the company’s published peer-reviewed study and taking a subtherapeutic intravenous level of a STING agonist and using it in conjunction with the Vesselon platform. This study resulted in getting 658% more drug into the tumor in a single flank tumor model with various associated other immune response benefits.
How can drug companies go about testing this platform for a drug candidate?
Vesselon CEO Clay Larsen, Epistat CEO Dr. Llew Keltner, and iECORE CEO Joseph Truitt discuss the timing and process for introducing Pharma drugs to the Vesselon platform.
What is the data to back the safety claims regarding co-formulatation with other drugs?
Vesselon CEO and Co-founder Clay Larsen discusses the original data safety package that was part of his company’s registrational filing for Imagent (TM) (i.e., “Imagent perflexane-lipid microspheres”).